(Total Views: 450)
Posted On: 04/01/2025 9:24:41 AM
Post# of 151556
From the new website:
CytoDyn is a publicly traded clinical stage biotechnology company developing innovative treatments utilizing leronlimab, a novel humanized monoclonal antibody that targets the CCR5 receptor. Leronlimab is being studied for its paradigm-shifting potential in solid-tumor oncology. The Company also strategically works with select partners to explore leronlimab’s potential benefits in certain inflammatory diseases. CytoDyn is committed to enhancing the lives of patients. Additional information about our Company and our development pipeline can be viewed at the links below.
"paradigm shifting potential in solid-tumor oncology"
"potential benefits in certain inflammatory diseases"
This serves as the mission statement. Now there is no question as to the dual mandates of Cytodyn. My guess is that HIV, and possibly long covid, are buried somewhere in the statement, but the primary uses of leronlimab are clear. This keeps things clean for shareholders, investors, and patients or potential patients.
Will there be an April letter to shareholders? I thinks so.
CytoDyn is a publicly traded clinical stage biotechnology company developing innovative treatments utilizing leronlimab, a novel humanized monoclonal antibody that targets the CCR5 receptor. Leronlimab is being studied for its paradigm-shifting potential in solid-tumor oncology. The Company also strategically works with select partners to explore leronlimab’s potential benefits in certain inflammatory diseases. CytoDyn is committed to enhancing the lives of patients. Additional information about our Company and our development pipeline can be viewed at the links below.
"paradigm shifting potential in solid-tumor oncology"
"potential benefits in certain inflammatory diseases"
This serves as the mission statement. Now there is no question as to the dual mandates of Cytodyn. My guess is that HIV, and possibly long covid, are buried somewhere in the statement, but the primary uses of leronlimab are clear. This keeps things clean for shareholders, investors, and patients or potential patients.
Will there be an April letter to shareholders? I thinks so.
(8)
(0)Scroll down for more posts â–¼
